Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Aspen sublicenses US Arixtra rights plus authorized generic to Mylan

08 May 2015

Executive Summary

Nearly a year after finalizing a definitive agreement to secure worldwide rights to Arixtra (fondaparinux), Aspen Global Inc. (the holding company for South African pharmaco Aspen Pharmacare Holdings Ltd.’s international businesses) licensed Mylan Inc., via its Mylan Ireland Ltd. division, US commercialization, marketing, and IP rights to the antithrombotic/anticoagulant agent, plus its authorized generic.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By